EA201892348A1 - COMBINATIONS AND METHODS INCLUDING THE CAPSIDE ASSEMBLY INHIBITOR - Google Patents

COMBINATIONS AND METHODS INCLUDING THE CAPSIDE ASSEMBLY INHIBITOR

Info

Publication number
EA201892348A1
EA201892348A1 EA201892348A EA201892348A EA201892348A1 EA 201892348 A1 EA201892348 A1 EA 201892348A1 EA 201892348 A EA201892348 A EA 201892348A EA 201892348 A EA201892348 A EA 201892348A EA 201892348 A1 EA201892348 A1 EA 201892348A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combinations
methods including
assembly inhibitor
capside
capside assembly
Prior art date
Application number
EA201892348A
Other languages
Russian (ru)
Other versions
EA037576B1 (en
Inventor
Джордж Хартман
Освальдо Флорес
Клаус Клумпп
Ман Лу Лам
Ян Мартин Берк
Original Assignee
Новира Терапьютикс, Инк.
Янссен Сайенсиз Айрлэнд Юси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новира Терапьютикс, Инк., Янссен Сайенсиз Айрлэнд Юси filed Critical Новира Терапьютикс, Инк.
Priority claimed from PCT/US2017/027802 external-priority patent/WO2017181141A2/en
Publication of EA201892348A1 publication Critical patent/EA201892348A1/en
Publication of EA037576B1 publication Critical patent/EA037576B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment

Abstract

Настоящее описание относится к композициям ингибиторов сборки капсида и способам их применения в лечении вирусной инфекции гепатита B.The present disclosure relates to capsid assembly inhibitor compositions and methods for their use in the treatment of hepatitis B virus infection.

EA201892348A 2016-11-11 2017-04-14 Combinations and methods comprising a capsid assembly inhibitor EA037576B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421035P 2016-11-11 2016-11-11
PCT/US2017/027802 WO2017181141A2 (en) 2016-04-15 2017-04-14 Combinations and methods comprising a capsid assembly inhibitor

Publications (2)

Publication Number Publication Date
EA201892348A1 true EA201892348A1 (en) 2019-03-29
EA037576B1 EA037576B1 (en) 2021-04-15

Family

ID=65950021

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190306A EA202190306A1 (en) 2016-11-11 2017-04-14 COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR
EA201892348A EA037576B1 (en) 2016-11-11 2017-04-14 Combinations and methods comprising a capsid assembly inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202190306A EA202190306A1 (en) 2016-11-11 2017-04-14 COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR

Country Status (1)

Country Link
EA (2) EA202190306A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519515B (en) * 2011-12-21 2016-02-01 諾維拉治療公司 Hepatitis b antiviral agents
SG11201504740UA (en) * 2012-12-27 2015-07-30 Univ Drexel Novel antiviral agents against hbv infection
JO3603B1 (en) * 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9181288B2 (en) * 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) * 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CN110483484A (en) * 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US9400280B2 (en) * 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections

Also Published As

Publication number Publication date
EA037576B1 (en) 2021-04-15
EA202190306A1 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
EA201691726A1 (en) NEW 6-CONDENSED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
MX2020011808A (en) Combinations and methods comprising a capsid assembly inhibitor.
EA201691261A1 (en) NEW DIHYDROCHINOLYSINES FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY THE HEPATITIS B VIRUS
JOP20180008A1 (en) Compounds for the treatment of hepatitis b virus infection
EA201791460A1 (en) N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION
MX2022011756A (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor.
MX2018005230A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon.
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
EA201691440A1 (en) AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
MX2018005569A (en) Vaccines against hepatitis b virus.
EA201790413A1 (en) ANTIBODIES AGAINST TIGIT
EA201790630A1 (en) METHODS OF OBTAINING RIBOSIDS
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
EA201690556A1 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS CAUSED BY INFECTIONS VIRUSED BY THE VIRUS
EA202090547A2 (en) MACROCYCLIC DEASE-OXIPURINS FOR TREATMENT OF VIRAL INFECTIONS
EA201690687A1 (en) REPLICATION INHIBITORS OF THE VIRUS OF IMMUNODEFICIENCY
EA202091849A1 (en) THIAZOLIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS
EA201692034A1 (en) NEW MACROCYCLIC COMPOUNDS
EA201692358A1 (en) IZOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTION
EA201690594A1 (en) COMPOSITION FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ATAZANAVIR AND COBICISTAT
JOP20190214A1 (en) subbstituted Dihydroindene-4-Carboxamides and Analogs Thereof, and Methods Using Same
EA201790776A1 (en) COMBINED COMPOSITIONS OF LONG-TERM ACTIONS AND METHODS OF TREATING HEPATITIS C
EA201790771A1 (en) PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FOR THE TREATMENT OF HEPATITIS C
EA201691777A1 (en) CONTAINING CYANOGRUPE COMPOUNDS AZABENZOFURANE FOR THE TREATMENT OF HEPATITIS C
EA201892348A1 (en) COMBINATIONS AND METHODS INCLUDING THE CAPSIDE ASSEMBLY INHIBITOR

Legal Events

Date Code Title Description
MA4A Surrender of the eurasian patent at the request of the proprietor in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU